抗體工程市場規模、佔有率及成長分析（按產品、製程、類型、最終用途和地區分類）－產業預測（2026-2033）

預計到 2024 年，抗體工程市場規模將達到 209.1 億美元，到 2025 年將達到 236.1 億美元，到 2033 年將達到 623.1 億美元，在預測期（2026-2033 年）內，複合年成長率為 12.9%。

抗體工程市場預計將迎來顯著成長，這主要得益於標靶治療、診斷和疫苗領域對抗體需求的激增。生物技術的進步以及對分子層面疾病機制的深入理解，凸顯了特異性抗體的重要性，這些抗體對於研究疾病路徑和推進個人化醫療至關重要。慢性病和感染疾病發病率的不斷上升進一步刺激了市場需求，而抗體在治療癌症、自體免疫疾病和其他疾病方面已展現出療效。精準醫療計劃也進一步提升了市場潛力。此外，重組DNA技術和高通量篩檢等技術創新正在簡化生產流程，提高擴充性和效率。總而言之，儘管仍存在一些挑戰，但醫療保健和製藥領域蘊藏著巨大的創新機會。

抗體工程市場促進因素

慢性病發病率的上升，以及人們對標靶治療日益成長的需求，正顯著推動抗體療法的需求成長。抗體具有獨特的特異性和療效，可用於治療多種疾病，包括癌症、自體免疫疾病和感染疾病。單株抗體（mAb）的進步和應用已徹底改變了治療方法，催生了許多以抗體技術為核心、療效顯著的藥物。隨著醫療系統尋求更有效的治療方案來應對複雜多樣的醫療挑戰，精準醫療的興起正在推動抗體工程市場的發展。

限制抗體生產市場的因素

抗體研發和生產的複雜流程、巨額研發投入以及對大規模生產能力的需求，導致成本高昂，為抗體生產市場帶來了巨大挑戰。高昂的成本阻礙了中小企業進入市場，限制了它們有效競爭的能力。此外，抗體生產的成本壁壘也限制了抗體治療方法的可近性和普及性。這種經濟壁壘最終會阻礙整個市場的成長，因為定價結構可能會使許多醫療服務提供者和患者無法受益於這些創新治療方法。

抗體生產市場趨勢

在對個人化醫療解決方案日益重視的推動下，抗體工程市場正經歷著向個人化醫療的重大轉變。基因組學和蛋白​​質組學技術的不斷進步提高了識別特定疾病標記的能力，從而促進了客製化標靶療法的開發。這一趨勢不僅提高了治療效果，還最大限度地減少了副作用，滿足了患者對更個人化治療方案的需求。因此，針對個別患者特徵客製化抗體的開發和生產正成為重點，隨著醫療保健越來越重視精準性和個人化，預計該市場將持續成長。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析
• 案例研究分析
• 專利分析

全球抗體生產市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 裝置
  • 生物反應器
  • 多用途生物反應器
  • 免洗生物反應器
  • 其他
• 層析法系統
• 過濾系統
• 消耗品
  • 媒體
  • 緩衝液和試劑
  • 層析法樹脂和色譜管柱
  • 過濾耗材及配件
  • 其他
• 軟體

全球抗體生產市場規模（按製程和複合年成長率分類）（2026-2033 年）

• 上游工程
• 下游工藝

全球抗體生產市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 多株抗體
• 單株抗體

全球抗體生產市場規模（按最終用途和複合年成長率分類）（2026-2033 年）

• 製藥和生物技術公司
• 研究所
• CROS 和 CDMOS

全球抗體生產市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• Roche（Switzerland）
• Genmab（Denmark）
• Amgen（US）
• Biogen（US）
• Johnson & Johnson（US）
• AbbVie（US）
• AstraZeneca（UK）
• Novartis（Switzerland）
• Pfizer（US）
• Sanofi（France）
• Merck & Co.（US）
• Gilead Sciences（US）
• Celgene（US）
• BioMarin Pharmaceutical（US）
• Shire（Ireland）
• Alexion Pharmaceuticals（US）
• Teva Pharmaceuticals（Israel）
• Allergan（US）
• Bristol Myers Squibb（US）
• Novo Nordisk（Denmark）

結論與建議

Antibody Production Market size was valued at USD 20.91 Billion in 2024 and is poised to grow from USD 23.61 Billion in 2025 to USD 62.31 Billion by 2033, growing at a CAGR of 12.9% during the forecast period (2026-2033).

The antibody production market is poised for significant growth, driven by the surging demand for antibodies essential in targeted therapies, diagnostics, and vaccines. Advances in biotechnology and a deeper understanding of molecular disease mechanisms highlight the necessity for specific antibodies, crucial for studying disease pathways and facilitating personalized medicine. The increasing incidence of chronic and infectious diseases amplifies this demand, with antibodies demonstrating efficacy in treating conditions like cancer and autoimmune disorders. The drive towards precision medicine further enhances market potential. Moreover, technological innovations, including recombinant DNA technology and high-throughput screening, are streamlining production processes, offering scalability and efficiency. Overall, while challenges persist, the market presents ample opportunities for innovation within the healthcare and pharmaceutical sectors.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antibody Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antibody Production Market Segments Analysis

Global Antibody Production Market is segmented by product, process, type, end use and region. Based on product, the market is segmented into instruments, chromatography systems, filtration systems, consumables and software. Based on process, the market is segmented into upstream processing and downstream processing. Based on type, the market is segmented into polyclonal antibody and monoclonal antibody. Based on end use, the market is segmented into pharmaceutical and biotechnology companies, research laboratories and cros and cdmos. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Antibody Production Market

The rising incidence of chronic illnesses, coupled with a growing preference for targeted treatment options, is significantly driving the demand for antibody-based therapeutics. Antibodies possess unique specificity and effectiveness for addressing a range of health conditions, such as cancer, autoimmune diseases, and infectious disorders. The advancement and application of monoclonal antibodies (mAbs) have transformed therapeutic approaches, leading to the introduction of several widely successful drugs that are centered around antibody technologies. This shift towards precision medicine is propelling the antibody production market, as healthcare systems seek more effective treatment solutions for complex and diverse medical challenges.

Restraints in the Antibody Production Market

The intricate processes involved in antibody development and production, alongside the substantial research and development investments and the necessity for large-scale manufacturing capabilities, lead to elevated costs that pose a considerable challenge within the antibody production market. These high expenses often hinder the participation of small and medium-sized enterprises, limiting their ability to compete effectively. Furthermore, the cost-prohibitive nature of antibody production restricts the affordability and accessibility of antibody-based therapies. This financial barrier consequently impedes overall market growth, as the pricing structures may prevent a wider range of healthcare providers and patients from benefiting from these innovative treatments.

Market Trends of the Antibody Production Market

The antibody production market is experiencing a significant shift towards personalized medicine, driven by an increasing emphasis on tailored healthcare solutions. As advancements in genomic and proteomic technologies continue to evolve, there is greater capability to identify specific disease markers, facilitating the creation of custom-targeted therapies. This trend not only enhances treatment efficacy but also minimizes side effects, resonating with patients' demand for more individualized care options. Consequently, the development and production of antibodies that can specifically address unique patient profiles is becoming a pivotal focus, positioning the market for continued growth as healthcare increasingly prioritizes precision and personalization.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Case Study Analysis
• Patent Analysis

Global Antibody Production Market Size by Product & CAGR (2026-2033)

• Market Overview
• Instruments
  • Bioreactors
  • Multi-Use Bioreactors
  • Single-Use Bioreactors
  • Others
• Chromatography Systems
• Filtration Systems
• Consumables
  • Media
  • Buffers And Reagents
  • Chromatography Resins And Columns
  • Filtration Consumables And Accessories
  • Others
• Software

Global Antibody Production Market Size by Process & CAGR (2026-2033)

• Market Overview
• Upstream Processing
• Downstream Processing

Global Antibody Production Market Size by Type & CAGR (2026-2033)

• Market Overview
• Polyclonal Antibody
• Monoclonal Antibody

Global Antibody Production Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Pharmaceutical And Biotechnology Companies
• Research Laboratories
• CROS and CDMOS

Global Antibody Production Market Size & CAGR (2026-2033)

• North America (Product, Process, Type, End Use)
  • USA
  • Canada
• Europe (Product, Process, Type, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Process, Type, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Process, Type, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Process, Type, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations